BCM
ORMP icon

BML Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

BML Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.17M Sell
866,269
-2,300,962
-73% -$9.16M 2.37% 11
2026
Q1 		$10.8M Hold
3,167,231
– – 6.91% 3
2025
Q4 		$9.03M Hold
3,167,231
– – 7.8% 3
2025
Q3 		$8.36M Buy
3,167,231
+83,978
+3% +$186K 7.66% 5
2025
Q2 		$6.94M Buy
3,083,253
+62,505
+2% +$138K 5.25% 6
2025
Q1 		$6.46M Buy
3,020,748
+376,841
+14% +$869K 5.23% 8
2024
Q4 		$6.4M Buy
2,643,907
+457,716
+21% +$1.09M 3.97% 9
2024
Q3 		$5.33M Buy
2,186,191
+837,153
+62% +$2.04M 3.14% 10
2024
Q2 		$3.47M Buy
1,349,038
+504,542
+60% +$1.2M 2.47% 10
2024
Q1 		$2.47M Sell
844,496
-417,063
-33% -$1.17M 1.63% 14
2023
Q4 		$2.91M Buy
1,261,559
+480,267
+61% +$1.03M 2.21% 12
2023
Q3 		$2.04M Sell
781,292
-68,708
-8% -$216K 1.87% 11
2023
Q2 		$3.04M Sell
850,000
-505,925
-37% -$1.62M 2.74% 12
2023
Q1 		$2.96M Buy
+1,355,925
New +$4.31M 2.56% 16

Other funds holding ORMP

Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $163M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

BML Capital Management's ORMP Position: Q2 2026 in Review

BML Capital Management reduced its Oramed Pharmaceuticals (ORMP) stake by 73% in Q2 2026, selling an estimated $9.16M and leaving 866,269 shares worth $4.17M. The position accounts for 2.37% of the portfolio, ranked #11.

BML Capital Management first reported a position in ORMP in Q1 2023 and has held it in 14 quarters since. The position peaked at $10.8M in Q1 2026. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

  • BML Capital Management held 866,269 shares of Oramed Pharmaceuticals worth $4.17M as of Q2 2026.
  • BML Capital Management sold 2,300,962 Oramed Pharmaceuticals shares in Q2 2026, an estimated $9.16M.
  • Oramed Pharmaceuticals made up 2.37% of BML Capital Management's portfolio in Q2 2026, its #11 holding.
  • BML Capital Management first reported a position in Oramed Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • BML Capital Management's Oramed Pharmaceuticals position peaked at $10.8M in Q1 2026.
  • 84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on BML Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.